DJIA 17,042.90 -28.32 -0.17%
NASDAQ 4,493.39 -12.46 -0.28%
S&P 500 1,972.29 -5.51 -0.28%
market minute promo


company name or ticker

Premature Combination Use Of Belviq And Phentermine Is A Risk

Belviq Sales Benefit From Advertising - Up 2.8%

VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog

3 Biotechs Investors Should Watch

The healthcare version of Where the Money Is.

VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session - Tale of the Tape

Vivus Up On Erectile Dysfunction Drug - What Should Investors Expect?

Today's Perilous Reversal Stock: Vivus (VVUS)

NASDAQ Biotech Top Performers (Pre-Open September 19)

Why VIVUS, Inc. Is Today's Best Biotech Stock

VIVUS stock is among today's top gainers after announcing the supplemental new drug approval for erectile dysfunction drug Stendra. Find out how this could impact VIVUS and its shareholders moving forward.

Why VIVUS (VVUS) Stock Is Up Today

See More Articles...